Accuray’s Radixact system obtains Japan Shonin approval

9 February 2017 (Last Updated February 9th, 2017 18:30)

Radiation oncology firm Accuray has secured Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for its Radixact treatment delivery system, Accuray Precision treatment planning system and iDMS data management system.

Radiation oncology firm Accuray has secured Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for its Radixact treatment delivery system, Accuray Precision treatment planning system and iDMS data management system.

The combination of the treatment delivery system and software solutions is expected to allow clinicians to provide accurate treatment to a wide range of cancer patients as well as to those undergoing retreatment.

The Radixact system is a fully-integrated, simplified adaptive treatment planning solution, which facilitates routine adjustment of treatment plans according to the changes in tumour size, shape and location.

"The newly approved advanced radiation therapy system is an easy to use and reliable device."

Accuray Japan president and general manager Juki Hozumi said: "With the introduction of the Radixact System, we are demonstrating significant progress in fulfilling on this promise.

"This new, mainstream System enables clinicians to deliver the highly sculpted doses for precise, customised treatments the previous TomoTherapy platform was known for, faster, enabling the treatment of more patients every day."

The newly approved advanced radiation therapy system is an easy to use and reliable device.

The system employs a linear accelerator, low-dose fan beam MVCT imaging and a helical treatment mode to enable clinicians to offer individualised dose distributions for all kinds of tumours.

According to a feedback received by the firm from its customers, Radixact system aids in providing precise radiation therapy to more patients in comparitively less time.

The system is now available in Japan, in addition to certain markets in the European Union and the US.